Additionally, several in vitro and in vivo studies have demonstrated the potential of DRD2 antagonists in other cancer types characterized by DRD2 upregulation including breast, prostatic, pancreatic, blood, oral, lung, gastric, and renal malignancies (149). This evidence concerns the gene DRD2 and cancer.